Precision Medicine Developer Secures Another Patent for Drug Candidate

Research Report
  ()
This company takes a step forward in its efforts to protect its intellectual property. read more >

Biotech Delivers Positive Study Results for Prostate Cancer Prognostic Test

Research Report
  ()
An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application. read more >

Biotech to Lead dMAB Tech Field with First Clinically Tested Product

Research Report
  ()
An H.C. Wainwright & Co. report discussed recent articles covering results of this firm's preclinical studies. read more >
News Update

Cannabis Provider to Debut Five More Dispensaries in Florida

News Update
  ()
This company plans to add even more this year as well. read more >

Neuromonitoring Stock 'Ready to Rally'

Contributed Opinion
  ()
Technical analyst Clive Maund charts a neuromonitoring company that he believes is undervalued. read more >
News Update

Biotech Ramps Up Philippine Sales of Livestock Feed Premix

News Update
  ()
A distributor of the proprietary product places a third large order. read more >
News Update

Biopharma to Accelerate Trial Timeline with Amendment

News Update
  ()
The change relates to the onset of dosing for patients with different degrees of disease. read more >

Biopharma Agrees to $215 Million Acquisition Deal

Research Report
  ()
An H.C. Wainwright & Co. report detailed the terms of the definitive agreement concerning the merger. read more >
News Update

Life Science Company Addresses Antibiotic Resistance Problem

News Update
  ()
This firm's proprietary technology provides an alternative to antibiotic use in livestock production. read more >
News Update

Biotech Files Patent Application for Nitric Oxide Delivery Device

News Update
  ()
With this development, the company advances blood/plasma transfusion technology. read more >
Expert Investing Ideas

"PMN is looking to outlicense PMN310 after the Phase 1 study."

–André Uddin, Mackie Research Capital


"DRRX intends to start a NASH trial as soon as H1/19."

–Francois Brisebois, Laidlaw & Company


"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"DRRX's total revenue for Q2/18 was $3.4M."

–Grant Zeng, Zacks Small-Cap Research


"We consider DRRX a development story."

–Francois Brisebois, Laidlaw & Company


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


"DRRX reported its Q1/18, mostly in line with expectations."

–Francois Brisebois, Laidlaw & Company


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Imprimis: Priming the Pumps for a Big 2019

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on. read more >

Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting

Research Report
  ()
A ROTH Capital Partners report relayed the contents of both presented abstracts. read more >

Catalysts Approaching for U.S. Developer of Cancer Therapeutics

Research Report
  ()
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch. read more >
News Update

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer

Research Report
  ()
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. read more >